Why Pfizer and BioNTech stocks popped Wednesday

The healthcare leaders became the first to receive emergency authorization for their coronavirus vaccine.

| More on:
woman waering face mask holding vial of covid-19 vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Shares of Pfizer Inc (NYSE: PFE) and BioNTech (NASDAQ: BNTX) climbed on Wednesday after the pharmaceutical titan and biotech announced a major development in the battle against COVID-19. As of 2:40 p.m. EST, Pfizer's and BioNTech's stocks were up 3% and 5.6%, respectively.

So what

A phase 3 trial showed Pfizer's and BioNTech's vaccine candidate BNT162b2 to be as much as 95% effective at preventing COVID-19. And importantly, BNT162b2 was generally well tolerated with no serious safety concerns observed among the study's participants to date. This promising data prompted the U.K. government to grant emergency authorization for the COVID-19 vaccine. 

"Today's Emergency Use Authorization in the U.K. marks a historic moment in the fight against COVID-19," Pfizer CEO Albert Bourla said in a press release. "This authorization is a goal we have been working toward since we first declared that science will win."

Pfizer and BioNTech have agreed to supply the U.K. with 40 million doses of the vaccine. The healthcare companies will begin delivering the vaccine immediately, with the first doses expected to arrive in the coming days. 

Now what 

The U.K.'s decision is a major step forward in the war against the dangerous disease. COVID-19 case counts remain at alarmingly high levels in many areas of the world. A safe and effective vaccine could help to slow the spread of the disease and eventually help to bring about an end to the pandemic.

Pfizer and BioNTech stand ready to deliver their vaccine to more countries in the weeks ahead. They have requested emergency authorization from health regulators in the U.S. and Europe. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are expected to announce their decisions later this month.

"As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world," Bourla said. "With thousands of people becoming infected, every day matters in the collective race to end this devastating pandemic."

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News

Man looks up at apple on his head.
International Stock News

Why the Google antitrust ruling could deal a blow to Apple's profits

An upcoming ruling in the case could severely affect a key high-margin revenue stream for the iPhone maker.

Read more »

Woman and man calculating a dividend yield.
International Stock News

Nvidia and Microsoft stocks have reached a $4 trillion valuation. Is Apple next?

Is Apple falling behind, or will it come from behind?

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
International Stock News

Should you buy Berkshire Hathaway while it's below $470?

The conglomerate's shares have fallen by roughly 15% from their 52-week high.

Read more »

Humanoid robot analysing the stock market, symbolising artificial intelligence shares.
International Stock News

After hitting $4 trillion, it took Nvidia just 1 month to gain another $480 billion in market cap. Is $5 trillion inevitable?

Nvidia's stock price is surging, putting pressure on the company to keep delivering impressive results.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

If you'd invested $1,000 in Berkshire Hathaway stock 5 years ago, here's how much you'd have today

Buying and holding quality stocks is a better bet than chasing hot growth trends.

Read more »

Amazon boxes stacked up on a doorstep.
International Stock News

Thinking of buying Amazon stock? Here's 1 green flag and 1 red flag.

Amazon stock may not be the pure retail bet it once was.

Read more »

A woman holds a soldering tool as she sits in front of a computer screen while working on the manufacturing of technology equipment in a laboratory environment.
International Stock News

Think Nvidia stock is expensive? These 2 charts might change your mind.

Is now the time to buy Nvidia stock?

Read more »

A woman sits at her desk thinking. She is surrounded by projections of world maps on various screens with data appearing below them.
Share Market News

Will ASX shares outperform global equities in FY26?

Global equities have delivered superior growth for 3 consecutive years. But is the tide turning?

Read more »